Gaps in Women’s Health Research Remain Despite Progress

by U.S. Medicine

November 14, 2010

WASHINGTON, DC—Research into women’s healthcare has improved over the last 20 years, but still lags in several key areas, according to an IoM report released last month. A concerted push to boost research on women’s health has had significant impacts on the burden of disease and deaths in areas such as cardiovascular disease, breast cancer, and cervical cancer. However, little progress has been seen in the areas of unintended pregnancies, autoimmune diseases, alcohol and drug addiction, lung cancer, and dementia.

According to IoM researchers, fewer gains have been made in chronic and debilitating conditions that cause significant suffering, but have lower death rates. This suggests that researchers need to give quality of life similar consideration as mortality when directing their research efforts.

Also, the report concludes that barriers such as socio-economic and cultural influences still limit the potential and reach of research developments, especially among more disadvantaged women.

“There is good news and bad news on the state of women’s health research,” said IoM committee chair Nancy E Adler, PhD, professor of medical psychology and director of the Center for Health and Community, University of California, San Francisco. “Significant boosts in research on women’s health issues have yielded measurable progress in reducing the toll of several serious disorders.  Unfortunately, less progress has been made on conditions that are not major killers but still profoundly affect women’s quality of life. These issues require similar attention and resources if we are to see better prevention and treatment.  And across all areas, researchers need to take into account the effects of both biologically determined sex differences and socially determined gender differences as a routine part of conducting research.” 

Much of the progress has been due to requirements for researchers to include women in studies. However, the full benefit of this has never been realized, since researchers do not routinely analyze and report results separately for women and men, the report noted. This limits the quality of the clinical information that could come out of these studies.

The report’s authors recommend that scientific journal editors require all papers reporting outcomes from clinical trials present data on men and women separately. They also recommend that FDA enforce companies’ compliance with requirements to provide sex-specific data on safety and efficacy of new drugs.

The IoM committee also recommended that HHS appoint a task force to develop strategies to communicate and market health messages about research results to women.

back to November articles

Comments are closed here.

Related Articles

Year Supply of Contraceptives Prevents More Unintended Pregnancies

Birth Control Pill Change Could Save VA $2 Million Annually PITTSBURGH—What if there was a method to prevent nearly 600 unintended pregnancies and save the VA about $2 million a year in prenatal, birth and... View Article

Feds Investigate 11 Unexplained Deaths at West Virginia VAMC

CLARKSBURG, WV – Law enforcement officials announced recently that a criminal investigation has been launched to look into the unexplained deaths of as many as 11 patients at the Louis A. Johnson VA Medical Center... View Article

U.S. Medicine Recommends

More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

Long-Acting Insulins Approved by FDA

PLAINSBORO, NJ – Physicians treating diabetes patients have new weapons in their arsenal.The Food and Drug Administration recently approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve glucose control in... View Article

FDA News

FDA Approves Option for Schizophrenia, Bipolar Treatment

JERSEY CITY, NJ – A new option for treating schizophrenia and bipolar disorder in adults has been approved by the Food and Drug Administration.The drug Vraylar, cariprazine in capsule form, is manufactured by Forest Laboratories... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

DHA Pharmacy Chief Says “Nefarious Actors” Targeted BeneficiariesBy Annette M. BoyleWASHINGTON — In April, the Defense Health Agency (DHA) spent $18 million a day in compound drug claims. By July, the daily costs had dropped... View Article

FDA News

FDA Approves Tecfidera for Treatment of Relapsing MS

WESTON, MA – The U.S. Food and Drug Administration has approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS). “No drug provides a cure for multiple sclerosis, so it... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up